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Abstract 
Despite the fact that the thyroid is a highly vascularized organ, clinically significant 
metastatic spread to the thyroid is considered uncommon. Hypothyroidism due to these 
metastases seldom occurs. A 68-year-old female patient came to our department 
because of rapid enlargement of the lower anterior part of the neck, which developed 
within 2 months. She had a history of poorly differentiated esophageal adenocarcinoma 
diagnosed 4 years ago, for which she underwent surgical removal of the neoplasm and 
received three cycles of chemotherapy. On physical examination, the clinical diagnosis 
was hypothyroidism with large, diffuse, firm goiter, and enlarged firm and fixed cervical 
lymph nodes. Thyroid and cervical ultrasound examination revealed significant diffuse 
enlargement of the thyroid, which was heterogeneous and hypoechogenic without focal 
lesions and multiple pathologically enlarged cervical lymph nodes. Laboratory 
examination revealed increased TSH levels with decreased free T4 and T3 levels. Fine 
needle aspiration biopsy of the thyroid revealed a metastatic adenocarcinoma. Our 
patient received external beam radiation therapy and chemotherapy, but unfortunately 
she passed away 4 months after diagnosis. Therefore, in case of a new (focal or diffuse) 
lesion in the thyroid gland in a patient with a history of malignant disease, regardless of 
the time elapsed since the diagnosis of the primary neoplasm, relapse of the preexisting 
disease must be considered until proven otherwise. 
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Introduction 
Despite the fact that the thyroid is a highly vascularized organ, clinically significant 
metastatic spread to the thyroid is considered uncommon. Hypothyroidism due to these 
metastases seldom occurs. 
Esophageal carcinoma is uncommon in the western world, but its prognosis is poor in 
the majority of patients, and mortality due to this neoplasm competes with mortality due 
to pancreatic carcinomas [1]. The thyroid gland is an unusual metastatic site for 
esophageal carcinoma [1]. We report a case of a female patient who developed severe 
hypothyroidism and diffuse goiter due to metastasis of her esophageal adenocarcinoma. 
Case Report 
A 68-year-old female patient came to our department because of a rapid enlargement in the anterior 
lower part of the neck, which developed within 2 months. She had a history of poorly differentiated 
esophageal adenocarcinoma diagnosed 4 years ago, for which she underwent surgical removal of the 
neoplasm and received chemotherapy without external beam radiotherapy (EBRT). Her follow-up for 
the esophageal adenocarcinoma did not reveal any relapse of the neoplasm until she was admitted to 
our department. 
At presentation, she reported easy fatigability and weakness. On physical examination, she had 
rough, dry skin, hoarseness, a heart rate of 64 beats/min and a large, diffuse, firm goiter associated with 
enlarged firm and fixed cervical lymph nodes. Laboratory analysis revealed increased TSH levels (TSH 
>50 mIU/l, normal values 0.17–4.05 mIU/l), decreased free T4 and T3 values (fT4: 6.2 pmol/l, normal 
values 11.5–23 pmol/l; fT3: 0.9 pmol/l, normal values 2.5–5.8 pmol/l), increased anti-thyroid antibodies 
(anti-Tg: >500 IU/ml, normal values <60 IU/ml; anti-TPO: >1,300 IU/ml, normal values <100 IU/ml) 
and normal calcitonin levels (calcitonin: 0.1 pg/ml, normal values <10 pg/ml). The tumor markers 
examined were within the normal limits. Her complete laboratory profile is outlined in table 1. 
Thyroid and cervical ultrasound examination revealed significant diffuse enlargement of the thyroid 
with a heterogeneous and hypoechogenic pattern without focal lesions (fig. 1, fig. 2) and cervical 
lymphadenopathy. A CT of the neck indicated a diffuse neoplasm surrounding and infiltrating the 
trachea. A chest CT unveiled metastatic lesions in both lungs. 
We performed fine needle aspiration biopsy (FNAB) of the thyroid (three passes in every lobe), and 
cytologically metastatic adenocarcinoma was found. Cytological samples did not unveil morphological 
characteristics of thyroid-derived malignant neoplasms (fig. 3). Immunostaining was negative for 
thyroglobulin, calcitonin, TTF1, K 5–6, CK20. 
Surgical debulking was not possible, so EBRT of the neck and upper mediastinum was initiated with 
concomitant administration of docetaxel and cisplatin. After completion of radiotherapy (total dose: 
3,900 cGy), six cycles of combination chemotherapy with irinotecan, oxaliplatin, 5-fluorouracil and 
folinic acid were scheduled at 28-day intervals. Two months after  EBRT termination, neck CT disclosed 
a partial response of the thyroid lesion, but the abdominal CT unveiled a hepatic metastatic lesion that 
did not exist before treatment initiation. Unfortunately, her clinical condition aggravated despite an 
initial partial response to EBRT and she passed away due to her disease after the second cycle of 
chemotherapy (4 months after diagnosis). 
Discussion 
The incidence of metastatic disease to the thyroid ranged from 1.25 to 24% in previous 
studies [2, 3]. Although the thyroid is a highly vascularized organ (being second after the 
adrenal gland), clinically significant metastases to the thyroid are uncommon [2–4]. 
Previously published studies on necrotic studies revealed that asymptomatic lesions are  
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not unusual, as we assumed in the past, and they seem to occur more frequently than 
primary carcinomas of the gland [2, 5]. Metastases to the thyroid frequently originate 
from the breast, lung and kidney. Several studies from autopsy series report that 
melanoma metastases are the most common, but these findings are not confirmed in 
clinical studies which indicate renal carcinomas to metastasize to the thyroid more 
frequently [2, 6, 7]. 
Metastatic lesions to the thyroid may appear many years after diagnosis of the primary 
tumor. Especially in case of renal malignancy, previous reports indicated that metastatic 
disease may develop 27 years after the diagnosis of a primary neoplasm [2, 6–8]. 
Metastatic dissemination occurs mainly by hematogenous spread or infiltration of 
adjacent tissue [8, 9]. Rarely, lymphatic or tumor-tumor dissemination may occur [8, 9]. 
Secondary lesions in the thyroid are usually solitary, while multifocal and diffuse 
lesions are rare. Thyroid function is not affected. Hypothyroidism due to metastases to 
the gland is uncommon and hyperthyroidism is even less frequent [10, 11]. In our patient, 
hypothyroidism was present at diagnosis and she was referred to our department for 
suspect goiter, these findings being the early and only manifestations of her metastatic 
disease which finally proved to be widespread. In the literature, goiter and 
hypothyroidism were the manifestations of metastatic disease, but hypothyroidism 
occurred later in the course of the disease, with patients being euthyroid at goiter 
diagnosis [12, 13]. We assume that, in our patient, massive invasion of the neoplasm led 
to severe hypothyroidism, probably due to preexisting, undiagnosed Hashimoto’s 
thyroiditis and impaired thyroid reserve. 
FNAB is an important tool in the diagnosis of metastatic disease. It is cheap and safe 
for the patient, and clinicians are able to define the nature of the neoplasm with accuracy 
[12–14]. Using FNAB, unnecessary thyroidectomy can be avoided in patients with a very 
poor prognosis [2, 13, 14]. The main limitation to the use of FNAB is that, sometimes, 
differential diagnosis between anaplastic thyroid carcinoma and metastatic lesions is 
difficult with this method [2]. Metastatic infiltration of the thyroid gland reflects a very 
poor prognosis (usually few months) because it appears in the context of widespread 
metastatic disease in most of the patients. However, in selected cases (mainly in 
metastases from renal carcinomas), surgical removal of solitary lesions may prolong 
survival [2, 6, 8]. 
Conventional therapeutic approaches seem to be ineffective for the treatment of 
metastases to the thyroid gland [2]. Although treatment must be individualized, 
aggressive surgical removal of metastases, where necessary and possible, and EBRT are 
the main therapeutic choices [2, 3, 15]. 
In conclusion, every new – focal or diffuse – lesion to the thyroid gland in a patient 
with a history of malignant disease, regardless of the time elapsed from the diagnosis of 
the primary neoplasm, must be considered as relapse of the preexisting disease until 
proven otherwise [2]. Also, in our opinion, metastatic disease to the thyroid must be 
borne in mind in the differential diagnosis of hypothyroidism in patients with known 
malignant disease.  
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Table 1. Laboratory profile of the patient at diagnosis 
Parameters Patient  Normal  range 
WBC, n/μl  013,900  004,000–11,000 
Neutrophils, n/μl  010,370  002,500–7,500 
Lymphocytes, n/μl  001,970  001,500–3,500 
Hemoglobin, g/dl  0000.13  00011.5–15.5 
Platelets, n/μl  667,000  150,000–400,000 
Urea, mg/dl  .000027  000.015–40 
Creatinine, mg/dl  0000...0.9  00000.6–1.1 
SGOT, U/l  000.018  0000.10–40 
SGPT, U/l  00000.8  .000010–35 
γGT, U/l  .000012  000.<30 
Alkaline phosphatase, U/l  000.075  .000040–150 
Bilirubin (total), mg/dl  0000...0.4   00000.2–1 
LDH, U/l  000.243  000.125–245 
Na, mmol/l  .000141  .000136–145 
K, mmol/l  0000...4.4  00003.5–5.1 
Ca, mg/dl  0000...8.9   00008.4–10.2 
P, mg/dl  0000...3.6   00002.7–4.5 
Albumin, g/dl  0000...4.4  00003.5–5 
Cholesterol, mg/dl  000.258  00.<200 
LDL cholesterol  00...175.6  .00<130 
HDL cholesterol  0000.63  000.>40 
Triglycerides  .000097  .00<150 
CPK, U/l  000.166  0000.38–174 
fT4, pmol/l  0000...6.2  00011.5–23 
fT3, pmol/l  0000...0.9  00002.5–5.8 
TSH, mIU/l  000.>50  0000.17–4.05 
Anti-TG, IU/ml  .00>500  000.<60 
Anti-TPO, IU/ml  0>1,300  .00<100 
Calcitonin, pg/ml  0000...0.1  0.00<10 
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Fig. 1. Ultrasonography of the right thyroid lobe. 
 
 
 
Fig. 2. Ultrasonography of the left thyroid lobe. 
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Fig. 3. Cytologic samples from our patient’s FNAB (Giemsa stain) without morphologic characteristics 
of thyroid-derived carcinoma. 
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